Related Experiment Video
Updated: Jul 28, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Cardiovascular Impact of Androgen Deprivation Therapy: from Basic Biology to Clinical Practice
Janice Kim1, Kendall Freeman1, Alyssa Ayala1
1Department of Medicine, City of Hope Comprehensive Cancer Center, Duarte, CA, 91010, USA.
Purpose Of The Review:
There have been increasing reports of cardiovascular complications of androgen deprivation therapy (ADT) leading to worse outcomes among patients with prostate cancer. While this may result from the direct effects of androgen suppression in the cardiovascular systems, there are ADT-type-specific distinct cardiovascular complications suggestive of mechanisms beyond androgen-mediated. Thus, it is critical to understand the biological and clinical impact of ADT on the cardiovascular system.
Recent Findings:
Gonadotropin-releasing hormone (GnRH) agonists cause increased cardiovascular events compared to GnRH antagonists. Androgen receptor antagonists are linked to an increased risk of long QT syndrome, torsades de pointes, and sudden cardiac death. Androgen synthesis inhibitors are associated with increased rates of hypertension, atrial tachyarrhythmia, and, in rare incidences, heart failure. ADT increases the risk of cardiovascular disease. The risk among ADT drugs differs and must be evaluated to develop a medically optimal plan for prostate cancer patients.
Insights
Androgen deprivation therapy (ADT) for prostate cancer increases cardiovascular risks. Different ADT types have distinct complications, necessitating careful drug selection for patient safety and optimal outcomes.
Area of Science:
- Cardiovascular Medicine
- Oncology
- Pharmacology
Background:
- Prostate cancer treatment often involves androgen deprivation therapy (ADT).
- Increasing reports link ADT to adverse cardiovascular outcomes in prostate cancer patients.
- Cardiovascular complications may stem from direct androgen suppression or distinct drug-specific mechanisms.
Purpose of the Study:
- To review the biological and clinical impact of ADT on the cardiovascular system.
- To highlight the differential cardiovascular risks associated with various ADT agents.
- To emphasize the importance of understanding these risks for optimal patient management.
Main Methods:
- Literature review of studies on ADT and cardiovascular complications.
- Analysis of cardiovascular event data associated with different ADT drug classes.
- Synthesis of evidence on mechanisms underlying ADT-related cardiovascular effects.
Main Results:
- Gonadotropin-releasing hormone (GnRH) agonists are associated with higher cardiovascular events than GnRH antagonists.
- Androgen receptor antagonists increase risks of long QT syndrome, torsades de pointes, and sudden cardiac death.
- Androgen synthesis inhibitors are linked to hypertension, atrial tachyarrhythmia, and heart failure.
Conclusions:
- ADT significantly increases cardiovascular disease risk in prostate cancer patients.
- The specific cardiovascular risks vary considerably among different ADT medications.
- Evaluating these drug-specific risks is crucial for developing personalized and medically optimal treatment plans.
Related Concept Videos
01:20Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
01:26Testosterone: Functions and Regulation
01:26Coronary Artery Disease II: Pathophysiology
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:17Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
01:29Hypertension II: Pathophysiology